Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 20/20 | 0.78 |
| ▸ | BCL2 | P10415 | 14/20 | 0.78 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.78 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935359 | 1.00 | MCL1 (0.78) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL14935245 | 1.00 | MCL1 (0.78) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL2367349 | 0.87 | MCL1 (1.00) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL14935309 | 0.87 | MCL1 (1.00) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL2368171 | 0.86 | MCL1 (1.00) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL2367188 | 0.86 | MCL1 (1.00) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL2367260 | 0.86 | MCL1 (1.00) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL14935611 | 0.86 | MCL1 (1.00) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL14935682 | 0.86 | MCL1 (1.00) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL2367939 | 0.85 | MCL1 (0.88) | MCL1BCL2BCL2L1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220088013-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088013-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | MCL1 30/4885BCL2 7/4885BCL2L1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.